0 CHECKOUT

General Anxiety Disorder - Pipeline Review, H1 2015

  • ID: 3231031
  • April 2015
  • 42 pages
  • Global Markets Direct
1 of 4

General Anxiety Disorder - Pipeline Review, H1 2015

Summary

This, ‘General Anxiety Disorder - Pipeline Review, H1 2015’, provides an overview of the General Anxiety Disorder’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for General Anxiety Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for General Anxiety Disorder and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes READ MORE >

Note: Product cover images may vary from those shown
2 of 4

List of Tables
List of Figures
Introduction
REPORT COVERAGE
General Anxiety Disorder Overview
Therapeutics Development
Pipeline Products for General Anxiety Disorder - Overview
Pipeline Products for General Anxiety Disorder - Comparative Analysis
General Anxiety Disorder - Therapeutics under Development by Companies
General Anxiety Disorder - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
General Anxiety Disorder - Products under Development by Companies
General Anxiety Disorder - Companies Involved in Therapeutics Development
Edgemont Pharmaceuticals, LLC
H. Lundbeck A/S
Pfizer Inc.
General Anxiety Disorder - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
EDG-008 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lorazepam ER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PF-06372865 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Modulate Glutamate Receptor for Anxiety Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tedatioxetine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
vortioxetine hydrobromide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
General Anxiety Disorder - Recent Pipeline Updates
General Anxiety Disorder - Dormant Projects
General Anxiety Disorder - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for General Anxiety Disorder, H1 2015
Number of Products under Development for General Anxiety Disorder - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
General Anxiety Disorder - Pipeline by Edgemont Pharmaceuticals, LLC, H1 2015
General Anxiety Disorder - Pipeline by H. Lundbeck A/S, H1 2015
General Anxiety Disorder - Pipeline by Pfizer Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
General Anxiety Disorder Therapeutics - Recent Pipeline Updates, H1 2015
General Anxiety Disorder - Dormant Projects, H1 2015
General Anxiety Disorder - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for General Anxiety Disorder, H1 2015
Number of Products under Development for General Anxiety Disorder - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

Edgemont Pharmaceuticals, LLC
H. Lundbeck A/S
Pfizer Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Pfizer Inc.
  • Grünenthal GmbH
  • GlaxoSmithKline PLC
  • Abbott Laboratories Ltd.
  • Roche Diagnostics Ltd.
  • Novo Nordisk A/S